Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Passage Bio — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Aug 01, 2024•almost 2 years ago

Contract Type

partnership

United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Description

Passage Bio, Inc. has out-licensed its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. and entered a new strategic research and collaboration agreement to advance genetic medicines for CNS indications, extending the operating cash runway to the end of Q2 2026.

Company Information

Company

Passage Bio

Location

United States

About

Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.

Predictive Intelligence
Strategic

ML-powered predictions for Passage Bio's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months